Acrivon Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M | -$16.2M |
| Operating expenses | $84.1M | $89.2M | $67.1M | $32.7M | $16.2M |
| Cash from operations | -$63.7M | -$65.7M | -$42.6M | -$30.1M | -$14.0M |
| Capital expenditure | $1.7M | $2.8M | $1.3M | $2.2M | $238,000 |
| Free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M | -$14.2M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M |
Shares outstanding 42.8M · Free float 81.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.